Article Text

Download PDFPDF
Next-generation metabolic imaging in pancreatic cancer
  1. Rickmer F Braren1,
  2. Jens T Siveke2,3
  1. 1 Institute of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
  2. 2 Division of Translational Solid Tumor Oncology, German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
  3. 3 Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
  1. Correspondence to Professor Jens T Siveke, Division of Translational Solid Tumor Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany; j.siveke{at}

Statistics from

In pancreatic ductal adenocarcinoma (PDAC), the lack of specific symptoms or diagnostic markers, the highly aggressive nature of the disease and high intrinsic and acquired therapy resistance all result in a virtually unchanged overall 5-year survival rate of around 5%.1 Thus, early detection of PDAC is a major task for improvement of prognosis and management of this fatal disease as surgery currently presents the only option for long-term survival.2 Conventional imaging techniques, including CT, proton-based MRI and endoscopic ultrasound, differentiate tumour tissue based on morphological and physiological (eg, reduced perfusion) changes, often not present in precursor lesions and early-stage tumours. Consequently, emerging innovative imaging technologies include molecular and metabolic approaches that allow the assessment of tumour biology.

Cancer phenotypes result from a host of mutational events, including signalling pathways that adapt tumour cell metabolism to support growth. One of these metabolic phenotypes observed in tumour cells is the Warburg effect, that is, ATP generation from glycolysis even under normal oxygen condition, converting most incoming glucose to lactate. Key pathways involved include phosphoinositide 3-kinase, hypoxia-inducible factor, p53, MYC and AMP-activated protein kinase. These alterations in glucose metabolism have been used in positron emission tomography (PET) imaging, in which the glucose analogue 18F-labelled fluorodeoxyglucose (18F-FDG) has been extensively applied in many cancer entities including PDAC. However, …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles